Fennec Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Fennec Pharmaceuticals Inc. (FENC) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-0.44-16.05-23.71-17.35-18.11-12.78-9.89
Depreciation & Amortization0.800.290.150.000.000.000.00
Stock Based Compensation5.065.354.223.752.880.000.00
Change in Working Capital16.94-6.781.10-0.93-0.660.570.13
Change in Accounts Receivable-7.87-7.27-1.550.000.000.000.00
Change in Inventory0.58-1.58-0.580.000.000.000.00
Change in Accounts Payable-0.541.391.61-0.79-0.040.000.00
Change in Other Working Capital0.210.681.610.28-0.620.000.00
Other Operating Activities0.215.390.280.280.400.060.00
Net Cash from Operating Activities26.98-17.14-18.06-14.22-15.60-9.06-7.83
Investing Activities
Net Cash from Investing Activities0.000.000.000.000.000.000.00
Financing Activities
Debt Repayment-13.005.00-5.000.000.000.000.00
Common Stock Issued0.001.720.930.0032.430.000.00
Common Stock Repurchased0.00-0.08-0.190.000.000.000.00
Other Financing Activities-1.92-0.08-0.18-0.06-0.14-0.070.02
Net Cash from Financing Activities-13.626.6420.734.9832.29-0.072.35
Summary
Net Change in Cash13.37-10.512.67-9.2416.69-9.13-5.48
Cash at Beginning of Period13.2723.7721.1030.3413.6522.7828.26
Cash at End of Period26.6313.2723.7721.1030.3413.6522.78
Free Cash Flow26.98-17.14-18.06-14.22-15.60-9.06-7.83